|
|
|
Volumn 53, Issue 9, 2008, Pages 695-696
|
|
Determining dose and endpoints of a controlled-release misoprostol vaginal insert for a phase III trial
a
|
|
Author keywords
Cervical ripening; Conrrolled release preparation; Induced labor; Misoprostol; Vaginal administration
|
|
Indexed keywords
MISOPROSTOL;
PROSTAGLANDIN E2;
ARTICLE;
CESAREAN SECTION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED RELEASE FORMULATION;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG DOSE COMPARISON;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
FETUS HEART RATE;
GASTROINTESTINAL SYMPTOM;
HUMAN;
LABOR INDUCTION;
PARITY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
UTERINE CERVIX RIPENING;
UTERINE HYPERSTIMULATION;
UTERINE HYPERTONIA;
UTERINE TACHYSYSTOLE;
UTERUS CONTRACTION;
UTERUS DISEASE;
VAGINAL DELIVERY;
ADMINISTRATION, INTRAVAGINAL;
CERVICAL RIPENING;
CLINICAL TRIALS, PHASE II AS TOPIC;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG APPROVAL;
FEMALE;
HUMANS;
MISOPROSTOL;
OXYTOCICS;
PARITY;
PREGNANCY;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
UNITED STATES;
|
|
EID: 53549112165
PISSN: 00247758
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (4)
|
